Clinical Trials Logo

Filter by:
NCT ID: NCT05612490 Recruiting - Acute Kidney Injury Clinical Trials

Furosemide Stress Test to Predict Successful Liberation From RRT

FST-RRT
Start date: January 17, 2023
Phase:
Study type: Observational

The proposed study will evaluate if a standardised dose of furosemide administered in the 12 hours after RRT liberation can predict successful liberation in critically ill patients. The dose that will be administered is in accordance with the prescribing information.

NCT ID: NCT05612256 Recruiting - Clinical trials for Positive End-expiratory Pressure (PEEP)

Electrical Impedance Tomography for Identification of Optimal Positive End-expiratory Pressure in Newborn Infants

Start date: December 10, 2022
Phase:
Study type: Observational

Electrical impedance tomography (EIT) enables assessment of regional lung ventilation at the bedside. EIT has been safely used in newborn infants to image intrathoracic lung volume patterns as early as from the first minute of life. This prospective single-centre observational study is to identify optimal PEEP in infants on respiratory support by measurements of EIT, FOT and SOPI.

NCT ID: NCT05612035 Recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

MK-5475-013 INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of MK-5475 (an Inhaled sGC Stimulator) in Adults With PH-COPD

Start date: March 16, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of once daily oral inhalation dose of MK-5475 380 µg in participants 40 to 85 years (inclusive) with Pulmonary Hypertension associated with Chronic Obstructive Pulmonary Disease (PH-COPD). The primary hypothesis of the study is MK-5475, a soluble Guanylate Cyclase (sGC) stimulator is superior to placebo in increasing 6 Minute Walking Distance (6MWD) from baseline at Week 24.

NCT ID: NCT05610631 Recruiting - Clinical trials for Pulmonary Hypertension

Pulmonary Hypertension Registry Switzerland

Start date: June 1, 2017
Phase:
Study type: Observational [Patient Registry]

Registry Data from PH-patients in Switzerland, who have given consent to records for research purposes.

NCT ID: NCT05609578 Recruiting - Clinical trials for Metastatic Lung Cancer

Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation

Start date: November 28, 2022
Phase: Phase 2
Study type: Interventional

Study CA239-0010 is an open-label, Phase 2 clinical trial evaluating the clinical efficacy of adagrasib in combination with pembrolizumab and chemotherapy in the first-line setting for patients with advanced NSCLC with TPS ≥ 1%, TPS <50% and KRAS G12C mutation

NCT ID: NCT05609214 Recruiting - Clinical trials for Coronary Artery Disease

Complementary Investigation of Perfusion and Anatomy Measures of the Heart With MRI and Combined PET/MRI

Start date: November 21, 2022
Phase:
Study type: Observational

The goal of this observational study is to evaluate the complimentary information of anatomy, perfusion and viability of PET and MR. The main question[s] it aims to answer are: - to compare perfusion and anatomy measurements and perfusion related signals from PET and MR imaging and estimate its prognostic values. - to evaluate potential optimization of routine scanning procedure with regards to completeness and potential added value of quantitative measurements.

NCT ID: NCT05609175 Recruiting - Diabetes Clinical Trials

Investigating the Relationship Between Nocturnal Glucose Levels and Motion During Sleep

Moonwalk
Start date: February 14, 2023
Phase:
Study type: Observational

In this study the investigators will explore whether the motion during sleep of people with diabetes changes as a function of the blood glucose levels. The motion will be assessed with a radar sensor, a thermal camera, and wrist worn smartwatches. Additionally, participants will answer a short daily questionnaire. Data will be collected for 10 days and analyzed at the end of the study.

NCT ID: NCT05608551 Recruiting - Motivation Clinical Trials

Animal-assisted Trauma-focused Therapy for Children and Adolescents

AA TF-CBT
Start date: October 1, 2022
Phase: N/A
Study type: Interventional

The study aims to investigate how the inclusion of an animal into a trauma-focused group therapy program (TF-CBT) affects therapy motivation of children and adolescents suffering from post-traumatic stress. 80 children and adolescents aged 9 to 17 years are recruited for the study. Participants must have experienced at least one traumatic event leading to post-traumatic stress symptoms. Participants are randomly allocated to one of two groups: animal-assisted trauma-focused therapy (AA TF-CBT) or standard trauma-focused therapy (TF-CBT). Parallel to the groups the parents/guardians of the participating children and adolescents take part in three parent meetings. The results of the study help to gain insights into how the inclusion of animals in trauma-focused psychotherapy can contribute to children and adolescents attending therapy, being more motivated in therapy, and can successfully complete therapy.

NCT ID: NCT05606588 Recruiting - Pediatric Cancer Clinical Trials

Preventing Sensory and Motor Dysfunctions in Children Receiving Neurotoxic Chemotherapy

PrepAIR
Start date: December 1, 2022
Phase: N/A
Study type: Interventional

The investigators would like to conduct a prospective, multicenter, two-armed trial (RCT with follow-up). Patients will be recruited from 7 centers (CH/D). All patients (and their guardians) scheduled to receive chemotherapy containing either a platinum derivate or vinca-alkaloid, will be asked to participate. Willing patients will then be randomized either into an intervention group or a control group. Patients in the intervention group will perform a standardized, age-adjusted, specific playful sensorimotor training (SMT) program twice a week for the duration of their medical therapy, in addition to usual care, while the control group receives treatment as usual. The CG will be given the opportunity to participate in the intervention after therapy. Data will be assessed at 3-4 time points: Prior to chemotherapy (baseline T0), after 12 weeks (T1), after completion of therapy for children that are treated >3 months (Tp) and after 12 months follow-up (T3). Additionally, status of Chemotherapy-induced peripheral neuropathy (CIPN) reported symptoms will be monitored twice in-between (6 weeks). The investigators hypothesize that less children in the intervention group will develop symptoms of CIPN (TNS score) with its debilitating side-effects. Furthermore, children in the intervention group will be able to maintain relevant motor and sensory functions and their associated physical functions which will enable them to receive their planned medical therapy but also to stay on the age-appropriate motor development level, improve their quality life and enhance social reintegration after therapy.

NCT ID: NCT05606523 Recruiting - Pancreatic Cancer Clinical Trials

Microbiota and Pancreatic Cancer Cachexia

EXTRA
Start date: August 1, 2022
Phase:
Study type: Observational

This monocentric study aims at evaluating the effects of fecal microbiota transplantation from newly diagnosed cachectic and non-cachectic pancreatic cancer patients, and healthy volunteers on several cachexia-related parameters of germ-free mice.